abciximab [aapp, imft, phsu]
Update [tmco]
Review [inpr]
ischaemic heart disease [dsyn]
abciximab [aapp, imft, phsu]
Glycoprotein IIb/IIIa Antagonist [chvf]
receptor [aapp, rcpt]
Proven [qlco]
To [qlco]
Clinical [qlco]
Value [qnco]
Improving [qlco]
Patient Outcome [idcn]
Percutaneous Coronary Revascularization [topp]
Drug [phsu]
arrested [dsyn]
Platelet aggregation [celf]
anticoagulant activity [moft]
effects [qlco]
Inhibiting [acty]
Migration [socb]
Promoting [acty]
Apoptosis [celf]
Smooth Muscle Cells [cell]
Large [qnco]
Well [qlco]
Design [acty]
studies [lbpr]
Found [qnco]
Administration [ocac]
abciximab [aapp, imft, phsu]
Heparin [bacs, carb, phsu]
Aspirin [orch, phsu]
Percutaneous Coronary Revascularization [topp]
Incidence [qnco]
Ischaemic [ftcn]
Complications [patf]
Occur [acty]
days [tmco]
Procedure [diap, topp]
Benefit [qnco]
Incidence [qnco]
Myocardial Infarction [dsyn]
Evidence [ftcn]
months [tmco]
Major [qlco]
Trial [resa]
abciximab [aapp, imft, phsu]
Benefit [qnco]
Patients [podg]
Angina, Unstable [dsyn]
Myocardial Infarction [dsyn]
Percutaneous Coronary Revascularization [topp]
Benefits [qnco]
Drug [phsu]
Additive [qlco]
coronary stenting [medd]
Very [qlco]
Preliminary [tmco]
Data [idcn]
Suggest [idcn]
abciximab [aapp, imft, phsu]
coronary [bpoc]
Blood flow [orgf]
Myocardial Infarction [dsyn]
Reperfusion [topp]
Reduced [qlco]
Thrombolytic [phsu]
Doses [qnco]
Required [ftcn]
To [qlco]
Risk [qlco]
Bleeding [patf]
Complications [patf]
abciximab [aapp, imft, phsu]
Combination [qlco]
Heparin [bacs, carb, phsu]
Aspirin [orch, phsu]
Care [acty]
Patient Selection [resa]
Appropriate [qlco]
Heparin [bacs, carb, phsu]
Regimen [topp]
Early [tmco]
vascular [bpoc]
Removal [topp]
Femoral Artery [bpoc]
access site [spco]
Care [acty]
Recommended [idcn]
Thrombocytopenia [fndg]
Occur [acty]
abciximab [aapp, imft, phsu]
treatment [ftcn]
Severe [qlco]
Cases [ftcn]
Uncommon [qlco]
Patients [podg]
treated [topp]
Transfusions, Platelet [topp]
High [qlco]
Acquisition [acty]
Cost [qnco]
abciximab [aapp, imft, phsu]
Offset [qnco]
Costs [qnco]
Reduced [qlco]
Incidence [qnco]
Ischaemic [ftcn]
Complications [patf]
Need [qlco]
Urgent [tmco]
Repeat [ftcn]
Revascularisation [topp]
High Risk [qlco]
Patients [podg]
Receive [qlco]
Drug [phsu]
Bleeding [patf]
Complications [patf]
Occur [acty]
ADD [mobd]
Treatment Costs [qnco]
Cost Effectiveness Analysis [ocac]
Support [medd]
abciximab [aapp, imft, phsu]
High Risk [qlco]
Patients [podg]
Conclusions [idcn]
abciximab [aapp, imft, phsu]
Recommended [idcn]
Prevention [topp]
acute [tmco]
Ischaemic [ftcn]
Events [evnt]
Patients [podg]
Percutaneous Coronary Revascularization [topp]
Care [acty]
Patient Selection [resa]
Adherence [ftcn]
Recommended [idcn]
Treatment Protocol [topp]
Required [ftcn]
To [qlco]
Risk [qlco]
Bleeding [patf]
Complications [patf]
Thrombocytopenia [fndg]
High Risk [qlco]
Patients [podg]
Supported [cnce]
pharmacoeconomic [qnco]
Data [idcn]
Further [spco]
pharmacoeconomic [qnco]
Information [idcn]
Needed [qlco]
To [qlco]
establish [qlco]
Drug [phsu]
Standard [qlco]
Care [acty]
Group [idcn]
Indications [idcn]
abciximab [aapp, imft, phsu]
Likely [qlco]
Expand [spco]
More [ftcn]
Data [idcn]
Syndromes, Acute Coronary [dsyn]
Available [ftcn]
